EVGN — Evogene Ltd.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1574565 ·
Last close
$0.34
Market Cap
$5.37M
52W High
$1.26
52W Low
$0.25
ADV30
413,700
Next earnings
2026-11-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 347,000 | 141,000 | -2,563,000 | -1,768,000 | 13,440,000 | 9,316,000 | 7,672,000 |
| Mar 2026 | 334,000 | 204,000 | -3,150,000 | -5,870,000 | 17,948,000 | 8,511,000 | 9,958,000 |
| Dec 2025 | 314,000 | -1,970,000 | -5,212,000 | -5,309,000 | 20,046,000 | 12,956,000 | 8,071,000 |
| Sep 2025 | 312,000 | 155,000 | -2,724,000 | 3,874,000 | 26,086,000 | 5,626,000 | 8,834,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,148,000
Investing CF
$3,562,000
Financing CF
$-9,158,000
CapEx
$-23,000
Dividends Paid
$-2,672,000
Buybacks
—
EPS Diluted TTM
$-0.91
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-290,194,000
Inventory
$93,000
Receivables
$1,125,000
ST Investments
$4,543,000
EBIT TTM
$-12,123,000
Pretax Income TTM
$-15,237,000
Interest Exp TTM
$3,114,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,657,000
EBITDA
$-13,971,000
Free Cash Flow
$-2,041,250
Enterprise Value
$8,341,558
Total Cash
$9,316,000
Total Debt
$2,101,000
Shares Out
15,801,407
Trailing EPS
$-1.75
Book Value
$-0.24
ROE
-182.7%
ROA
-37.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,853,000 | -14,034,000 | -8,485,000 | 20,046,000 | 8,071,000 | -82,000 | -13,502,000 |
| Dec 2024 | 5,577,000 | -18,757,000 | -16,485,000 | 39,864,000 | 25,026,000 | -1,451,000 | -19,700,000 |
| Dec 2023 | 2,982,000 | -22,205,000 | -23,879,000 | 51,101,000 | 22,416,000 | 12,053,000 | -21,577,000 |
| Dec 2022 | 1,675,000 | -26,941,000 | -26,638,000 | 56,126,000 | 21,336,000 | 27,930,000 | -23,678,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MTEX | MANNATECH INC | $5.46M | $2.83 | — |
| BIOT | INSTINCT BIO TECHNICAL CO HOLDINGS INC. | $5.21M | $0.18 | — |
| NAII | NATURAL ALTERNATIVES INTERNATIONAL INC | $5.64M | $0.90 | — |
| GURE | GULF RESOURCES, INC. | $4.84M | $2.67 | — |
| BON | Bon Natural Life Ltd | $6.51M | $1.07 | — |
News headlines (Yahoo Finance, 1h cache)
Evogene Schedules Third Quarter 2026 Financial Results Release
2026-11-05 12:00 · Yahoo
Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
2026-10-28 12:30 · Yahoo
Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain
2026-10-26 12:00 · Yahoo
Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL
2026-10-20 12:00 · Yahoo
Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward
2026-08-31 12:00 · Yahoo
Evogene (EVGN) Q2 2026 Earnings Call Transcript
2026-08-25 11:45 · Yahoo
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
2026-08-25 11:00 · Yahoo
Evogene Ltd. Q2 2026 Earnings Call Summary
2026-08-19 12:30 · Yahoo
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
2026-08-14 11:00 · Yahoo
AgPlenus Announces Significant Progress in Its Fungicide Discovery Programs Targeting New Modes of Action, with Activity Against Resistant Septoria and Additional Fungal Pathogens
2026-11-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.